These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9164968)

  • 1. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
    Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
    J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
    Marquart HV; Svehag SE; Leslie RG
    J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
    Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
    J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
    Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses.
    Qin D; Wu J; Carroll MC; Burton GF; Szakal AK; Tew JG
    J Immunol; 1998 Nov; 161(9):4549-54. PubMed ID: 9794381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the complement C3 protein in the control of the specific immune response].
    Villiers CL; Villiers MB; Marche PN
    Ann Biol Clin (Paris); 1999; 57(2):127-35. PubMed ID: 10210739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity.
    Papp K; Végh P; Prechl J; Kerekes K; Kovács J; Csikós G; Bajtay Z; Erdei A
    Mol Immunol; 2008 Apr; 45(8):2343-51. PubMed ID: 18192019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.
    Delibrias CC; Fischer E; Bismuth G; Kazatchkine MD
    J Immunol; 1992 Aug; 149(3):768-74. PubMed ID: 1386093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
    Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
    Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CR2 ligands modulate human B cell activation.
    Bohnsack JF; Cooper NR
    J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
    Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
    Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.
    Nielsen CH; Marquart HV; Prodinger WM; Leslie RG
    Immunology; 2001 Dec; 104(4):418-22. PubMed ID: 11899427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.
    Leslie RG; Prodinger WM; Nielsen CH
    Eur J Immunol; 2003 Dec; 33(12):3311-21. PubMed ID: 14635039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structural basis for complement receptor type 2 (CR2, CD21)-mediated alternative pathway activation of complement: studies with CR2 deletion mutants and vaccinia virus complement-control protein-CR2 chimeras.
    Johnson AA; Mirowski Rosengard A; Skjodt K; Ahearn JM; Leslie RG
    Eur J Immunol; 1999 Dec; 29(12):3837-44. PubMed ID: 10601991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein.
    Huemer HP; Wang Y; Garred P; Koistinen V; Oppermann S
    Immunology; 1993 Aug; 79(4):639-47. PubMed ID: 8406590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.